e8vk
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
Current Report Filed Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934
Date of Report
(Date of earliest event reported): July 14, 2008
Repros Therapeutics Inc.
(Exact name of registrant as specified in its charter)
| |
|
|
|
|
| Delaware
|
|
001-15281
|
|
76-0233274 |
| |
|
|
|
|
(State or other jurisdiction of
incorporation or organization)
|
|
(Commission File Number)
|
|
(I.R.S. Employer Identification No.) |
2408 Timberloch Place, Suite B-7
The Woodlands, Texas 77380
(Address of principal
executive offices
and zip code)
(281) 719-3400
(Registrant’s telephone
number, including area
code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the
filing obligation of the registrant under any of the following provisions (see General Instruction
A.2 below):
| o |
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| |
| o |
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| |
| o |
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| |
| o |
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Item 7.01. Regulation FD Disclosure
Repros Therapeutics Inc. (the “Company”) announced today that it will host an analyst meeting
for the financial community beginning at 10:00 a.m. Eastern Time on Thursday, July 24, 2008 in New
York City. The event, which is by invitation only, will focus on the Company’s clinical drug
candidate Proellex®. There will be a live video webcast of the event, and it will be subsequently
archived for at least one month on the Company’s website.
A copy of the Company’s press release is attached hereto as Exhibit 99.1. The press release
is incorporated by reference herein and the foregoing description of the press release is qualified
in its entirety by reference to the attached exhibit.
Item 9.01. Financial Statements and Exhibits
d. Exhibit
| |
|
|
| Exhibit |
|
|
| Number |
|
Description |
99.1
|
|
Press Release dated July 14, 2008. |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly
caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| |
|
|
|
|
| |
|
Repros Therapeutics Inc. |
|
|
|
|
|
Date: July 14, 2008 |
|
|
|
|
|
|
|
|
|
|
|
By:
|
|
/s/ Louis Ploth, Jr. |
|
|
|
|
|
|
|
|
|
Louis Ploth, Jr. |
|
|
|
|
Vice President, Business Development and |
|
|
|
|
Chief Financial Officer |
EXHIBIT INDEX
| |
|
|
| Exhibit |
|
|
| Number |
|
Description |
99.1
|
|
Press Release dated July 14, 2008. |